Publications by authors named "S Cotteret"

Introduction: Microsatellite instability (MSI) is a genetic marker that is useful in the detection and treatment of Lynch syndrome (Sd). Although conventional techniques such as immunohistochemistry (IHC) and polymerase chain reaction (PCR) are the standards for MSI detection, the advent of next-generation sequencing (NGS) has offered new possibilities, especially with circulating DNA.

Case Report: We present the case of a 26-year-old patient with Lynch Sd and a -mutated metastatic colon cancer.

View Article and Find Full Text PDF

Mullerian adenosarcoma is a rare malignant biphasic tumor. The mesenchymal component may be low or high grade, with or without sarcomatous overgrowth (SO). Little is known about the molecular heterogeneity of these tumors.

View Article and Find Full Text PDF

As a promising alternative to bone marrow aspiration (BMA), mutational profiling on blood-derived circulating cell-free tumor DNA (cfDNA) is a harmless and simple technique to monitor molecular response and treatment resistance of patients with refractory/relapsed multiple myeloma (R/R MM). We evaluated the sensitivity and specificity of cfDNA compared to BMA CD138 positive myeloma plasma cells (PCs) in a series of 45 R/R MM patients using the 29-gene targeted panel (AmpliSeq) NGS. , , , , and were the most frequently mutated genes.

View Article and Find Full Text PDF
Article Synopsis
  • Next-generation sequencing (NGS) using plasma cell-free DNA (cfDNA) is vital for identifying mutations in advanced solid cancer patients, revealing mutations that tissue tests may miss.
  • In a study with 542 participants, about 51.8% had "liquid biopsy-only mutations," especially in genes like TP53 and DDR, indicating these patients were typically older and received more treatment.
  • These mutations, although low in frequency, showed specific patterns and were partially validated in whole blood samples, highlighting the complexity and unique nature of interpreting liquid biopsy results.
View Article and Find Full Text PDF

Introduction: Small cell lung cancer (SCLC) accounts for 15% of lung cancers worldwide. It is an aggressive tumor that is typically diagnosed at an advanced stage. Treatment involves chemo-immunotherapy and/or radiotherapy.

View Article and Find Full Text PDF